Streamline Health Solns (NASDAQ:STRM) reported quarterly sales of $6.00 million which beat the analyst consensus estimate of $5.16 million by 16.28 percent. This is a 101.75 percent increase over sales of $2.97 million the same period last year.
Here’s How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.
